Education
About Us
Working with TipRanks
Follow Us
Surrozen (SRZN)
NASDAQ:SRZN
SRZN Stock Chart & Stats
$13.70
$0.24(1.85%)
At close: 4:00 PM EST
$13.70
$0.24(1.85%)
Day’s Range― - ―
52-Week Range$5.90 - $18.17
Previous CloseN/A
Volume12.23K
Average Volume (3M)25.24K
Market Cap
$116.39M
Enterprise Value-$6.52M
Total Cash (Recent Filing)$90.39M
Total Debt (Recent Filing)$7.51M
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Nov 17, 2025EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.55
Shares Outstanding8,570,355
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-0.52
Enterprise Value/Gross Profit-0.49
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$37.00Price Target Upside170.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Industry ValidationStrategic validation of the Wnt pathway has been demonstrated by acquisitions from major companies like Merck and Roche, supporting the Wnt mechanism.
Partnerships And CollaborationsThe collaboration and licensing agreement with Boehringer Ingelheim for bi-specific antibody SZN-413 provides upside beyond the internal Wnt pipeline for vascular pathology.
Research And DevelopmentThe company recently presented preclinical data for assets SZN-8141 and SZN-8143 at major annual meetings, indicating progress in their research focus.
Bears Say
Clinical Development DelaysThe internal clinical development is on the longer-term horizon with candidate SZN-8141 IND submission anticipated in 2026, suggesting a delay in market availability.
Discontinued ProjectsSurrozen previously discontinued former lead candidate SZN-043 based on Phase 1b development for severe alcohol-associated hepatitis, indicating challenges in certain therapeutic areas.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $5.90 and its highest was $18.17 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $116.39M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Nov 17, 2025 which is in 24 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on Aug 08, 2025. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of -$1.11 by $3.66.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.14.
How many shares outstanding does Surrozen have?
Surrozen has 8,570,355 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of $2.55 in its last earnings report, beating expectations of -$1.11. Following the earnings report the stock price went up 4.393%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
Surrozen Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$37.00 (170.07% Upside)
$37.00 (170.07% Upside)
Hedge Fund Trend
Decreased
By 213.9K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
-130.27%
Trailing 12-Months
Asset Growth
127.85%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$37.00
▲(170.07% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
29.20% Insiders
2.80% Mutual Funds
48.79% Other Institutional Investors
16.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---